French Court Denies Roche Action Over Avastin In AMD

A judge at France's top administrative court, the Conseil d'Etat, has denied a request from Roche to suspend the government's decision to reimburse its anticancer, Avastin (bevacizumab), for the off-label indication of wet age-related macular degeneration (AMD)1.

A judge at France's top administrative court, the Conseil d'Etat, has denied a request from Roche to suspend the government's decision to reimburse its anticancer, Avastin (bevacizumab), for the off-label indication of wet age-related macular degeneration (AMD)1.

The Swiss firm had asked the court to suspend the temporary use recommendation (Recommandation Temporaire d'Utilisation, or RTU) allowing Avastin's...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet